Antonio Facciorusso1, Sunil Roy2, Sarantis Livadas3, Adwalia Fevrier-Paul4, Clara Wekesa5, Ismail Dogu Kilic6, Amit Kumar Chaurasia7, Mina Sadeq8, Nicola Muscatiello9. 1. Gastroenterology Unit, Department of Medical Sciences, University of Foggia, AOU Ospedali Riuniti, Viale Pinto, 1, 71100, Foggia, Italy. antonio.facciorusso@virgilio.it. 2. Belhoul Speciality Hospital, Dubai, United Arab Emirates. 3. Athens Medical School, Evgenideio Hospital, Athens, Greece. 4. College Green, Kingston, Jamaica. 5. Uganda Research Unit on AIDS, Entebbe, Uganda. 6. Pamukkale University, Denizli, Turkey. 7. Bl Kapoor Superspeciality Hospital, New Delhi, India. 8. National Institute of Hygiene, Rabat, Morocco. 9. Gastroenterology Unit, Department of Medical Sciences, University of Foggia, AOU Ospedali Riuniti, Viale Pinto, 1, 71100, Foggia, Italy.
Abstract
BACKGROUND: The role of nonselective beta-blockers in cirrhotic patients with ascites has been recently questioned; however, definitive evidence in this regard is still lacking. AIMS: To analyze published data on the influence of nonselective beta-blockers as compared to control group on survival of cirrhotic patients with ascites. METHODS: Computerized bibliographic search on the main databases was performed. Hazard ratios from Kaplan-Meier curves were extracted in order to perform an unbiased comparison of survival estimates. Secondary outcomes were mortality in patients with refractory ascites, pooled rate of nonselective beta-blockers interruption, spontaneous bacterial peritonitis and hepato-renal syndrome incidence. RESULTS: Three randomized controlled trials and 13 observational studies with 8279 patients were included. Overall survival was comparable between the two groups (hazard ratio = 0.86, 0.71-1.03, p = 0.11). Study design resulted as the main source of heterogeneity in sensitivity analysis and meta-regression. Mortality in refractory ascites patients was similar in the two groups (odds ratio = 0.90, 0.45-1.79; p = 0.76). No difference in spontaneous bacterial peritonitis (odds ratio = 0.78, 0.47-1.29, p = 0.33) and hepato-renal syndrome incidence (odds ratio = 1.22, 0.48-3.09; p = 0.67) was observed. Pooled rate of nonselective beta-blockers interruption was 18.6% (5.2-32.1%). CONCLUSIONS: Based on our findings, nonselective beta-blockers should not be routinely withheld in patients with cirrhosis and ascites, even if refractory.
BACKGROUND: The role of nonselective beta-blockers in cirrhotic patients with ascites has been recently questioned; however, definitive evidence in this regard is still lacking. AIMS: To analyze published data on the influence of nonselective beta-blockers as compared to control group on survival of cirrhotic patients with ascites. METHODS: Computerized bibliographic search on the main databases was performed. Hazard ratios from Kaplan-Meier curves were extracted in order to perform an unbiased comparison of survival estimates. Secondary outcomes were mortality in patients with refractory ascites, pooled rate of nonselective beta-blockers interruption, spontaneous bacterial peritonitis and hepato-renal syndrome incidence. RESULTS: Three randomized controlled trials and 13 observational studies with 8279 patients were included. Overall survival was comparable between the two groups (hazard ratio = 0.86, 0.71-1.03, p = 0.11). Study design resulted as the main source of heterogeneity in sensitivity analysis and meta-regression. Mortality in refractory ascitespatients was similar in the two groups (odds ratio = 0.90, 0.45-1.79; p = 0.76). No difference in spontaneous bacterial peritonitis (odds ratio = 0.78, 0.47-1.29, p = 0.33) and hepato-renal syndrome incidence (odds ratio = 1.22, 0.48-3.09; p = 0.67) was observed. Pooled rate of nonselective beta-blockers interruption was 18.6% (5.2-32.1%). CONCLUSIONS: Based on our findings, nonselective beta-blockers should not be routinely withheld in patients with cirrhosis and ascites, even if refractory.
Authors: Thomas Reiberger; Arnulf Ferlitsch; Berit A Payer; Mattias Mandorfer; Birgit B Heinisch; Hubert Hayden; Frank Lammert; Michael Trauner; Markus Peck-Radosavljevic; Harald Vogelsang Journal: J Hepatol Date: 2012-12-20 Impact factor: 25.083
Authors: Joanna A Leithead; Neil Rajoriya; Nadeem Tehami; James Hodson; Bridget K Gunson; Dhiraj Tripathi; James W Ferguson Journal: Gut Date: 2014-10-03 Impact factor: 23.059
Authors: Guruprasad P Aithal; Naaventhan Palaniyappan; Louise China; Suvi Härmälä; Lucia Macken; Jennifer M Ryan; Emilie A Wilkes; Kevin Moore; Joanna A Leithead; Peter C Hayes; Alastair J O'Brien; Sumita Verma Journal: Gut Date: 2020-10-16 Impact factor: 23.059
Authors: David Kockerling; Rooshi Nathwani; Roberta Forlano; Pinelopi Manousou; Benjamin H Mullish; Ameet Dhar Journal: World J Gastroenterol Date: 2019-02-28 Impact factor: 5.742